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A B S T R A C T
Treatment of severe acute respiratory syndrome
(SARS) is experimental, and the effectiveness of
ribavirin–steroid therapy is unclear. Forty SARS
patients with progressive disease after ribavirin
treatment and 1.5 g of pulsed methylprednisolone
were given either convalescent plasma (n = 19) or
further pulsed methylprednisolone (n = 21) in a
retrospective non-randomised study. Good clin-
ical outcome was defined as discharge by day 22
following the onset of symptoms. Convalescent
plasma was obtained from recovered patients
after informed consent. Patients in the plasma
group had a shorter hospital stay (p 0.001) and
lower mortality (p 0.049) than the comparator
group. No immediate adverse effects were
observed following plasma infusion.
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In Hong Kong, the first major outbreak of severe
acute respiratory syndrome (SARS) commenced
on 10 March 2003 in the Prince of Wales Hospital,
with > 130 persons becoming infected [1]. This
highly infectious respiratory illness was caused
by a novel coronavirus [2,3]. Treatment was
mainly empirical and, in the Prince of Wales
Hospital, ribavirin and steroids were used as first-
line treatment to suppress viral replication and
minimise autoimmune pneumonitis. In c. 74% of
the patients, the ribavirin–steroid combination
was associated with recovery [4]. However, there
was great debate as to whether ribavirin was
effective against coronavirus, as well as concern
about the side effects of high-dose steroids.
Patients with persistent fever, radiographic pro-
gression and hypoxaemia, despite receiving 1.5 g
of methylprednisolone, responded poorly to fur-
ther courses of high-dose steroids, and an alter-
native therapy was needed. It was postulated that
convalescent plasma from recovered SARS
patients would carry antibodies against the
coronavirus and might suppress viraemia.
A retrospective comparison study was per-
formed on SARS patients admitted between
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10 March and 10 April 2003. The patients were
treated empirically with ribavirin and methyl-
prednisolne [4]. Inclusion criteria were as follows:
SARS diagnosed according to the Centers for
Disease Control guidelines [5]; and clinical and
radiographic deterioration despite ribavirin
and three doses (500 mg each) of pulsed
methylprednisolone. Patients who had received
intravenous immunoglobulin, pentaglobulin, pro-
tease inhibitors or fewer than three doses of
methylprednisolone were excluded. The patients
studied were given either convalescent plasma
(plasma group) or further pulses of methylpredn-
isolone (steroid group) at the discretion of the
attending clinicians and according to the availab-
ility of convalescent plasma. The potential bene-
fits and side effects of convalescent plasma were
explained carefully to the patients and their
families. Patients in the plasma group could
receive pulsed steroids if their condition wor-
sened after plasma therapy, and were then
classed as plasma therapy failures. Similarly, if
patients in the steroid arm deteriorated after
further pulses of methylprednisolone, they could
receive convalescent plasma, but were then
classed as steroid therapy failures.
Following informed consent, convalescent plas-
ma was obtained from patients who had recov-
ered from SARS, and who were seronegative for
hepatitis B, hepatitis C, HIV and syphilis. All
serum donors were seropositive for coronavirus
(titre 160–2560). Apharesis was performed with a
CS 300 cell separator (Baxter, Deerfield, IL, USA),
with 600–900 mL of plasma obtained from each
donor. Based on experience with Ebola virus [6],
200–400 mL of convalescent plasma was used to
treat each of the recruited patients.
Good response to therapy was defined as
discharge by day 22 following the onset of SARS
symptoms. Poor response was defined as death or
hospitalisation beyond 22 days. Discharge cri-
teria, according to Hospital Authority guidelines,
were as follows: afebrile for 4 consecutive days;
improvement of previously abnormal laboratory
tests (white cell counts, platelet counts, creatinine
phosphokinase, lactate dehydrogenase, liver func-
tion tests and C reactive protein); radiographic
improvement; and a period of at least 21 days
following the onset of illness, since there is
evidence that coronavirus is still detectable in
the stools of some recovered patients for up to
3 weeks [7].
The charts were reviewed and data entered
independently by the first two authors. Treatment
outcome, age and lactate dehydrogenase levels on
admission were compared between patients in the
plasma group and those in the steroid group.
Numerical data were compared by the independ-
ent samples Student t-test, and categorical data
were compared by Fisher’s exact test. Differences
were considered significant at the level of
p < 0.05.
Nineteen patients received convalescent plas-
ma after three doses of pulsed methylpredniso-
lone (plasma group); two also received
additional pulsed steroids. Nine patients in the
steroid group (n = 21) were given convalescent
plasma subsequently after four to eight doses of
pulsed methylprednisolone. Age, sex and lactate
dehydrogenase levels on admission were com-
parable between the two groups (Table 1). In
the plasma group, 74% of patients were dis-
charged by day 22, compared with 19% in the
steroid group (p 0.001; Table 2). Five people
died in the steroid group, all of whom were
patients who received steroids only, compared
with no deaths in the plasma group (p 0.049).
Nine patients in the steroid group who received
Table 2. Comparison of treatment outcome between pa-
tients in the plasma-treated and steroid-treated groups
Plasma groupa Steroid groupb p
Discharge rate by day 22
following onset of illness
73.4%
(n = 14)
19%
(n = 4)
0.001
Discharge rate by day 22
after adjustment for
co-morbidities
77.8%
(14 ⁄ 18)
23%
(3 ⁄ 13)
0.004
Death rate 0% 23.8%
(n = 5)
0.049
aThree doses of methylprednisolone, followed by convalescent plasma.
bFour or more doses of methylprednisolone.
Table 1. Clinical demographics of patients in the plasma-
treated and steroid-treated groups
Plasma groupa Steroid groupb p
No. of patients 19 21
Age (years) 38.7 ± 12.39 47.9 ± 19.60 0.087
Admission LDH (IU ⁄L) 256.1 ± 90.75 247.7 ± 94.58 0.7
Co-morbiditiesc 1 (DM, old TB) 1 SLE,
2 DM with old TB,
4 hypertension,
1 atrial fibrillation
0.05
aThree doses of methylprednisolone, followed by convalescent plasma.
bFour or more doses of methylprednisolone.
cTwo patients were hepatitis B carriers (one in each group), but without clinical
evidence of cirrhosis; they were not considered as having co-morbidities.
DM, diabetes mellitus; LDH, lactate dehydrogenase; SLE, systemic lupus erythe-
matosus; TB, tuberculosis.
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convalescent plasma were given it in the third
week of the disease (mean 15.56 days), while
those in the plasma group usually received the
sera in the second week (mean 11.42 days;
p < 0.001). Patients receiving convalescent plas-
ma after day 16 had a poor clinical response.
No immediate adverse effects were observed
following the infusion of convalescent plasma.
In most viral illnesses, viraemia peaks in the
first week of infection. The patient then develops
a primary immune response by day 10–14, fol-
lowed by virus clearance. Therefore, convalescent
plasma should be more effective when given early
in the course of the disease. In SARS, viral load
also peaks in the first week [5], and this might
explain the lack of clinical effectiveness of conva-
lescent plasma when given after day 16.
There were several limitations to this study.
First, it was not a randomised study and the
steroid group had more co-existing morbidities.
However, when the analysis was repeated after
excluding patients with co-morbid illness in
each group, the difference in clinical outcome
remained statistically significant (p 0.004). Sec-
ond, the amount of antibodies given to each
patient was not standardised, which could con-
tribute to the variable clinical outcome in patients
receiving convalescent plasma. Finally, it is argu-
able whether the ribavirin–steroid combination
was effective at all in SARS patients, and the
poorer outcome in the continuing high-dose
methylprednisolone group might be caused sim-
ply by the deleterious effects of steroids. How-
ever, no fungal or opportunistic infections were
observed in these patients.
In summary, these preliminary data showed
that convalescent plasma therapy was associated
with a more favourable outcome in SARS
patients who deteriorated despite ribavirin and
high-dose steroid therapy than continuing high-
dose methylprednisolone. A larger randomised
study is required to confirm these preliminary
results.
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